signed advanced purchase agreements for 170 million doses of the Sinopharm BIBP vaccine, 350 million doses of CoronaVac, and 414 million doses of SCB-2019, another COVID-19 vaccine in Phase III trials. All of these actions have been a component in enacting China's strategy of enacting mask diplomacy, where the state has distributed medical supplies, including Covid-19 vaccines, and financial support to other European countries, in an effort to restore China's historically maligned and recently ignominious image. While on the other hand, these actions have demonstrated that China is a pragmatic, self-driven problem solver, willing to establish alliances with other nations contrasting the United States’ isolationist policies. In addition, China is utilizing this opportunity to distance, and even shift the narrative regarding the start of Covid-19, promoting its successes on its political model when compared to the West. India By late March 2021, India had produced 125 million doses of COVID-19 vaccines and had exported 55 million doses. 84 countries had received vaccines from India, either through COVAX, grants or regular purchases. India sent millions of doses of Covid-19 vaccine to 95 countries including neighboring Bhutan, Afghanistan, Nepal, Bangladesh, Sri Lanka, Myanmar and the Maldives. India will also supply vaccines to Pakistan through COVAX initiative. During the second wave of the COVID-19 pandemic in India, the Vaccine Maitri program was put on hold until July 2021 due to increased number of COVID cases in India. As of 29 May 2021, India had exported 66.4 million doses including 10.7 million vaccine provided as grant to more than 95 nations. India's health ministry said the country will resume COVID-19 vaccine exports as a part of COVAX and Vaccine Maitri initiative, by October, promising supply development that comes ahead of high-level talks this week on solving vaccine inequity gaps, while World Health Organization chief Tedros Adhanom Ghebreyesus has hailed India's decision to resume COVID-19 vaccine exports as an “important development” in support of the goal to reach 40 per cent vaccination in all countries by end of the year. Mexico Secretary of Foreign Affairs of Mexico Marcelo Ebrard announced agreements with CanSino Biologics and Walvax to conduct clinical trials for vaccines from China, with the possibility of the manufacturing the vaccines in the country. Marcelo Ebrard also announced agreements with Johnson & Johnson to trial its U.S. developed vaccine in Mexico. Japan In July 2020, Japan agreed to provide 11.6 billion yen (US$109million) to